Market Overview

Regeneron Pharmaceuticals Spokesperson Declines Comment on Earlier Takeover Chatter

Share:
Related REGN
Alimera's Commercial Steroid Implant For Diabetic Macular Edema, Explored
Barron's Picks And Pans: Drug Stocks, Hanesbrands, Wabtec And More
Related SNY
Exondys Sales, Takeover Speculation Fuel Sarepta Therapeutics
Earnings Scheduled For April 28, 2017

Regeneron (NASDAQ: REGN) spokesperson Peter Dworkin, while declining comment on earlier takeover chatter involving Sanofi (NYSE: SNY), did say that the two companies have a solid working relationship and have stated it would be advantageous to keep the relationship going as it is now, as separate companies.

Sanofi is Regeneron's largest shareholder currently. There is a standstill agreement in place preventing Sanofi from acquiring more than 30% of Regeneron's shares.

Regeneron shares spiked to a high of $145.81 on Thursday.

Posted-In: News Rumors M&A Movers

 

Related Articles (REGN + SNY)

View Comments and Join the Discussion!